• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets.

作者信息

Hodson David J, Rorsman Patrik

机构信息

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Edgbaston, U.K.

Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, U.K.

出版信息

Diabetes. 2020 May;69(5):864-866. doi: 10.2337/dbi19-0035.

DOI:10.2337/dbi19-0035
PMID:32312904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7171971/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/7171971/5991884fce7a/dbi190035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/7171971/5991884fce7a/dbi190035f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/7171971/5991884fce7a/dbi190035f1.jpg

相似文献

1
A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets.主题变奏：人胰岛中的SGLT2抑制与胰高血糖素分泌
Diabetes. 2020 May;69(5):864-866. doi: 10.2337/dbi19-0035.
2
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.SGLT2 不在胰腺的 α-和 β-细胞中表达，其抑制作用不会直接影响啮齿动物和人类的胰高血糖素和胰岛素分泌。
Mol Metab. 2020 Dec;42:101071. doi: 10.1016/j.molmet.2020.101071. Epub 2020 Sep 5.
3
No direct effect of SGLT2 activity on glucagon secretion.SGLT2 活性对胰高血糖素分泌无直接影响。
Diabetologia. 2019 Jun;62(6):1011-1023. doi: 10.1007/s00125-019-4849-6. Epub 2019 Mar 22.
4
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.用达格列净抑制胰岛α细胞中的葡萄糖转运蛋白 SGLT2 可触发胰高血糖素的分泌。
Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20.
5
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.SGLT1 在胰腺 α 细胞中调节小鼠的胰高血糖素分泌，这可能解释了 SGLT2 抑制剂对血浆胰高血糖素水平的不同影响。
Mol Metab. 2019 Jan;19:1-12. doi: 10.1016/j.molmet.2018.10.009. Epub 2018 Oct 27.
6
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.人胰岛中 SGLT2 表达和功能的个体间异质性。
Diabetes. 2020 May;69(5):902-914. doi: 10.2337/db19-0888. Epub 2020 Jan 2.
7
SGLT2 inhibition and glucagon secretion in humans.SGLT2 抑制与人类胰高血糖素分泌。
Diabetes Metab. 2018 Nov;44(5):383-385. doi: 10.1016/j.diabet.2018.06.005. Epub 2018 Jun 30.
8
Dapagliflozin Does Not Directly Affect Human α or β Cells.达格列净不会直接影响人α或β细胞。
Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa080.
9
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.达格列净以 SGLT2 非依赖方式调节小鼠胰岛α细胞中的胰高血糖素分泌。
Diabetes Metab. 2017 Dec;43(6):512-520. doi: 10.1016/j.diabet.2017.04.002. Epub 2017 May 9.
10
Pancreatic α-cells - The unsung heroes in islet function.胰腺α细胞——胰岛功能中的无名英雄。
Semin Cell Dev Biol. 2020 Jul;103:41-50. doi: 10.1016/j.semcdb.2020.01.006. Epub 2020 Jan 24.

引用本文的文献

1
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.糖尿病合并神经内分泌肿瘤患者的肠促胰岛素和钠-葡萄糖协同转运蛋白2抑制剂：最新进展与未来方向
Rev Endocr Metab Disord. 2025 Apr 2. doi: 10.1007/s11154-025-09958-5.
2
Role of Glucagon in the Effects of SGLT2 Inhibition on Potassium and Magnesium Homeostasis.胰高血糖素在SGLT2抑制对钾和镁稳态影响中的作用。
Kidney Med. 2024 Aug 13;6(9):100888. doi: 10.1016/j.xkme.2024.100888. eCollection 2024 Sep.
3
The relationship between SGLT2 and systemic blood pressure regulation.

本文引用的文献

1
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.人胰岛中 SGLT2 表达和功能的个体间异质性。
Diabetes. 2020 May;69(5):902-914. doi: 10.2337/db19-0888. Epub 2020 Jan 2.
2
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
3
Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells.
SGLT2 与全身血压调节之间的关系。
Hypertens Res. 2024 Aug;47(8):2094-2103. doi: 10.1038/s41440-024-01723-6. Epub 2024 May 23.
4
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.库欣综合征、肢端肥大症和神经内分泌肿瘤继发糖尿病的实用治疗方法。
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
5
SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases.钠-葡萄糖协同转运蛋白2抑制剂用于非糖尿病患者严重低镁血症的治疗：4例报告
Kidney Med. 2023 Jul 1;5(9):100697. doi: 10.1016/j.xkme.2023.100697. eCollection 2023 Sep.
6
Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对重度慢性肾脏病、透析或肾移植患者是否有效且安全？
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1500-1502. doi: 10.2215/CJN.0000000000000221. Epub 2023 Jun 14.
7
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials.药物研发的教训：非酒精性脂肪性肝病 (NAFLD) 临床试验中面临挑战的文献综述。
Int J Mol Sci. 2022 Dec 21;24(1):158. doi: 10.3390/ijms24010158.
8
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.SGLT2 抑制剂在伴有糖尿病肾病的 1 型糖尿病中的应用：潜在的心肾获益可能超过可预防的糖尿病酮症酸中毒风险。
Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.
9
TIGER: The gene expression regulatory variation landscape of human pancreatic islets.TIGER：人类胰岛的基因表达调控变异景观。
Cell Rep. 2021 Oct 12;37(2):109807. doi: 10.1016/j.celrep.2021.109807.
10
Mechanisms controlling pancreatic islet cell function in insulin secretion.控制胰岛素分泌的胰岛细胞功能的机制。
Nat Rev Mol Cell Biol. 2021 Feb;22(2):142-158. doi: 10.1038/s41580-020-00317-7. Epub 2021 Jan 4.
激动剂诱导的膜纳米域聚类驱动胰腺β细胞中的 GLP-1 受体反应。
PLoS Biol. 2019 Aug 20;17(8):e3000097. doi: 10.1371/journal.pbio.3000097. eCollection 2019 Aug.
4
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.GLP1R 激动剂利拉鲁肽通过生长抑素释放减少 SGLT2 抑制剂达格列净引起的高胰高血糖素血症。
Cell Rep. 2019 Aug 6;28(6):1447-1454.e4. doi: 10.1016/j.celrep.2019.07.009.
5
No direct effect of SGLT2 activity on glucagon secretion.SGLT2 活性对胰高血糖素分泌无直接影响。
Diabetologia. 2019 Jun;62(6):1011-1023. doi: 10.1007/s00125-019-4849-6. Epub 2019 Mar 22.
6
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.胰岛素通过 SGLT2 诱导的生长抑素分泌刺激抑制胰高血糖素释放。
Nat Commun. 2019 Jan 11;10(1):139. doi: 10.1038/s41467-018-08193-8.
7
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.SGLT1 在胰腺 α 细胞中调节小鼠的胰高血糖素分泌，这可能解释了 SGLT2 抑制剂对血浆胰高血糖素水平的不同影响。
Mol Metab. 2019 Jan;19:1-12. doi: 10.1016/j.molmet.2018.10.009. Epub 2018 Oct 27.
8
Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production.高血糖诱导的钠依赖性三磷酸腺苷产生减少导致胰高血糖素分泌失调。
Cell Metab. 2019 Feb 5;29(2):430-442.e4. doi: 10.1016/j.cmet.2018.10.003. Epub 2018 Nov 8.
9
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.2 型糖尿病患者短期 SGLT2 抑制时的胰高血糖素水平主要受血糖变化的调节。
J Clin Endocrinol Metab. 2019 Jan 1;104(1):193-201. doi: 10.1210/jc.2018-00969.
10
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.达格列净以 SGLT2 非依赖方式调节小鼠胰岛α细胞中的胰高血糖素分泌。
Diabetes Metab. 2017 Dec;43(6):512-520. doi: 10.1016/j.diabet.2017.04.002. Epub 2017 May 9.